Recludix is also advancing a potential first-in-class BTK SH2 domain inhibitor for B cell or mast cell-driven I&I diseases, as well as additional discovery programs. Recludix was named a 2024 Fierce ...

Financing led by institutional investors, with participation from new investor Eli Lilly and Company Inclusive of this investment, a total of $123 million in equity financing received from ...

SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today ...